NCT05676450 2025-10-31
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
M.D. Anderson Cancer Center
Phase NA Recruiting